

The Price of Autonomy:^{*}

Liability Standards for Complementary and Substitutive Medical Robotics and Artificial Intelligence

Frank Pasquale^{**}

Abstract

When AI or robotics assist a professional, they are tools. In medicine, the doctrine of “competent human intervention” has tended to shift liability away from those who make devices and toward the professionals who use them. However, the professional in such scenarios should not bear the entire burden of responsibility. Tools can be defective, and vendors of defective, complementary AI and robotics should be held responsible for negligence. The burden of proof should still be on the plaintiff to demonstrate that not only a skilled medical professional, but also the maker of the tools used by such a professional, should be held liable for a preventable adverse outcome.

When AI and robotics replace, rather than merely assist, a skilled medical professional, the vendor of such computational systems needs to take on more responsibility for errors and accidents. In the medical field,

* Submission Date: July 31, 2019; Acceptance Date: January 3, 2023. [Line Editor: You syuan Lu & Chia Yo Yan].

I wish to thank expert audiences at National Taiwan University and Academia Sinica for greatly enriching my understanding of this area. I also wish to thank anonymous peer reviewers and Anita Bernstein for thoughtful comments. Any errors remain my own responsibility. By mutual agreement of all publication venues, a version of this article has also appeared in *The Cambridge Handbook of Artificial Intelligence: Global Perspectives on Law and Ethics*, and in *Ius et Praxis*.

** Professor of Law, Cornell Tech and Cornell Law School.

Online: <https://publication.ias.sinica.edu.tw/31017032.pdf>.



there has long been a standard of competent professional supervision of the deployment of advanced technology. When substitutive automation endangers patients by short-circuiting that supervision, it is both defective and unreasonably dangerous. Nevertheless, at the damages phase of litigation, the vendor of the substitutive AI should be entitled to explain how damages should be mitigated based on its AI's performance relative to the extant human- or human-machine-based standard of care. Such responsibility for explanation will serve an important information-forcing function in areas where public understanding is often limited by trade secrecy.

As law and political economy methods demonstrate, law cannot be neutral with respect to markets for new technology. It constructs these markets, making certain futures more or less likely. Distinguishing between technology that substitutes for human expertise and that which complements professionals is fundamental not just to labor policy and the political economy of automation, but also to tort law.

KEYWORDS: artificial intelligence (AI), robotics, liability, automation, automated decision making, malpractice, enterprise liability, professions, political economy, clinical decision support software.

Contents

- I. Introduction
- II. A Negligence Standard for Complementary Robotics
- III. Strict Liability for Substitutive Automation
- IV. Concluding Remarks: Virtues of a Mixed Negligence-Strict Liability Regime

I. Introduction

There are now robotic applications for nursing home patients, the mentally ill, and other vulnerable populations. These advanced technologies raise critical liability questions for the medical profession. Consider the case of robotically assistive surgical devices (RASDs) which surgeons use to control small cutting and grasping devices. If a surgeon's hand slips with a scalpel, and a vital tendon is cut, our intuitive sense is that the surgeon bears the primary responsibility for the resultant malpractice suit. But the vendor of an RASD may eventually market a machine which has a special "tendon avoidance subroutine," akin to the alarms that automobiles now sound when their sensors indicate a likely collision. If the tendon sensors fail, and the warning does not sound before an errant cut is made, may the harmed patient sue the vendor of the RASD? Or only the physician who relied on it?

Similar problems arise in the context of some therapy apps. For example, a counselor may tell a patient with substance use disorder (SUD) to use an app in order to track cravings, states of mind, and other information helpful to those trying to cure addictions. The app may recommend certain actions in case the counselor cannot be reached. If these actions are contraindicated and result in harm to the patient or others, is the app to blame? Or the doctor who prescribed it? Or both? Home health care businesses may encounter similar dilemmas as they deploy so-called "care robots."¹

¹ For a fascinating overview of legal issues raised by care robots, see Valarie K. Blake, *Regulating Care Robots*, 92 TEMP. L. REV. 551 (2020). For examples of medical automation gone awry, see ROBERT WACHTER, *THE DIGITAL DOCTOR: HOPE, HYPE, AND HARM AT THE DAWN OF MEDICINE'S COMPUTER AGE* (2015).

Of course, in neither the surgical nor the mental health scenario is the answer necessarily binary. There may be shared liability, based on an apportionment of responsibility. But before courts can trigger such an apportionment, they must have a clear theory upon which to base the responsibility of vendors of technology.

This article develops such an approach. What is offered here is not a detailed blueprint for liability determinations in any particular jurisdiction. Instead, this article presents a binary approach toward ideal-typical liability situations intended to structure policy discussions on liability for harm caused by AI and robotics in medical contexts.² The binary is the distinction between substitutive and complementary automation.³ When AI and robotics substitutes for a physician, strict liability is more appropriate than standard negligence doctrine. When the same technology merely assists a professional, a less stringent standard is appropriate. Such standards will help ensure that the deployment of advanced medical technologies is accomplished in a way that complements extant professionals' skills, while promoting patient safety.

As law and political economy methods demonstrate, law cannot be neutral with respect to markets for new technology.⁴ It constructs these

2 This article will draw on common law principles in many jurisdictions, in order to inform a general policy discussion. It does not attempt to give detailed legal guidance, or map how courts presently do handle cases involving AI and complex computation in medical contexts. Rather, cases and other legal materials are drawn upon to illustrate the complement/substitute distinction.

3 This distinction may also be styled as a contrast between artificial intelligence (AI) and intelligence augmentation (IA). However, that contrast would probably confuse matters at present, given that much of what is called AI in contemporary legal and policy discussions is narrow enough to be IA.

4 See Martha T. McCluskey, Frank Pasquale & Jennifer Taub, *Law and Economics: Contemporary Approaches*, 35 YALE L. & POL'Y REV. 297 (2016).

markets, making certain futures more or less likely. Distinguishing between technology that substitutes for human expertise and that which complements professionals is fundamental to both labor policy and the political economy of automation.

For example, in the case of computerized physician order entry (CPOE) for prescriptions, a “drug-drug interaction” alert (DDI) could simply warn a physician about possible side effects from simultaneous ingestion of two pills.⁵ That is complementary automation. If the DDI alert were, in fact, incorrect, a harmed patient could sue both the physician and the vendor of the CPOE system, but the burden should be on the patient to demonstrate the CPOE system’s vendor failed to follow the proper standard of care in updating data or improving algorithms in order to avoid the problem. And the physician might still bear all or most of the responsibility, under the doctrine of competent human intervention.

By contrast, some CPOE systems of the future may simply “decide everything” with respect to the prescription of the two pills, preventing the doctor from prescribing them together. In such a scenario, the physician is no longer responsible—she or he cannot override the system. Given this extraordinary deviation from ordinary professional standards in medicine—which require a skilled person to mediate between technology and the patient—it is appropriate to impose strict liability up and down the distribution chain of such a substitutive AI. Under a strict liability standard, in case of a preventable adverse event, the manufacturer, distributor, and retailer of the product may be liable, even if they were not at fault.

⁵ For a good typology of potential scenarios arising in the context of assistive AI, see generally W. Nicholson Price, II, Sara Gerke & I. Glenn Cohen, *Potential Liability for Physicians Using Artificial Intelligence*, 322 JAMA 1765 (2019).

This may seem like an unduly harsh standard. However, the doctrine of strict liability arose in response to those who sold “any product in a defective condition unreasonably dangerous to the user or consumer or to his property.”⁶ In the medical field, there has long been a standard of competent professional supervision and monitoring of the deployment of advanced technology.⁷ When substitutive automation short-circuits that review, it is both defective and unreasonably dangerous. It also tends toward the diminution of the distributed expertise so critical to medical advance.⁸

This article develops the complementary and substitutive categories via two case studies. Part II explores the complementary role of RASDs, and some litigation that has arisen regarding them. Part III introduces substitutive AI and robotics, and demonstrates the ways in which strict liability standards are likely necessary to promote accountability in their development and deployment, to preserve a unitary standard of care, and to promote public awareness of their shortcomings. Part IV concludes with reflections on the current utility of, and potential challenges to, the substitutive/complementary dichotomy.

6 RESTATEMENT (SECOND) OF TORTS § 402A (AM. L. INST. 1979).

7 This article addresses policymakers governing health systems with this standard of care. Those in charge of less developed health systems (coping with physician or other staff shortages) may well decide that strict liability is too harsh a standard: if there is no viable human alternative, why discourage direct access to a machine? Those in many of the more developed health systems need to acknowledge their own responsibility for this state of affairs. See Frank Pasquale, *Access to Medicine in an Era of Fractal Inequality*, 19 ANNALS HEALTH L. 269 (2010) (describing direct and indirect ways in which medical resources are directed away from the developing and toward the developed world).

8 For an extended argument for the ideal of distributed expertise, see generally FRANK PASQUALE, *NEW LAWS OF ROBOTICS: DEFENDING HUMAN EXPERTISE IN THE AGE OF AI* (2020).

II. A Negligence Standard for Complementary Robotics

Prostate surgery has seen rapid adoption of robotics with over 80% of the surgeries are performed robotically. Hundreds of urological surgeons have adopted the Da Vinci Surgical Robot over the past decade. The rapid adoption of the RASDs in prostate surgery demonstrates just how fast a new machine can change the face of practice for hundreds of thousands of patients.⁹

At the outset, it is important to be clear about the terminology and effects of machines like the da Vinci robot. The device itself does not complete the surgery. Rather, it is an extremely sophisticated tool deployed by a skilled surgeon. The surgeon operates at a console, manipulating instruments from afar. What distinguishes robotic surgery from its predecessor, laparoscopic surgery, is that rather than merely deploying a tube with a cutter and a grabber at each end, the surgeon using an RASD has more dexterity—the device can twist around and act as a second wrist or eleventh finger. These RASDs took off at first in urology, because many urological and gynecological procedures involve very sensitive tissue that can only be accessed through a small opening

⁹ See Gina Kolata, *Results Unproven, Robotic Surgery Wins Converts*, N.Y. TIMES (Feb. 13, 2010), <http://www.nytimes.com/2010/02/14/health/14robot.html?pagewanted=1&hp;compare> Giacomo Novara et al., *Systematic Review and Meta-analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Prostatectomy*, 62 EUR. UROLOGY 431 (2012), with *Surgical Robots Market Size, Share & Trends Analysis Report By Application (Orthopedics, Neurology, Urology, Gynecology), By Region (North America, Europe, Asia Pacific, LATAM, MEA), and Segment Forecasts, 2023 – 2030*, GRAND VIEW RES. (Apr. 2016), <http://www.grandviewresearch.com/industry-analysis/surgical-robot-market>. Legal scholarship addressing the surgical robotics market includes Andrew Chin, *Surgically Precise but Kinematically Abstract Patents*, 55 HOUS. L. REV. 267 (2017) (describing how intellectual property law helps enable monopolistic business practices).

at the base of the pelvic bowl. The device can achieve forms of movement and illumination of tissue that would be impossible using human hands alone.

That is not to say that the transition from open to robotic prostatectomy was an easy one. Surgeons who had worked their entire lives through direct manual touch had to adopt their practice to what could start off as an unintuitive imaging and manipulation system. At the beginning, for many surgeons, the lack of direct touch—the so-called haptic interface—made surgery more difficult or time-consuming. However, over time, surgeons developed the ability to detect other cues for the feel of tissue—for example, how quickly it moves once probed, or how blood vessels blanch when the metallic ends of the robotic probe contact them. For a surgeon who has already seen and more directly prodded bodily tissue hundreds or thousands of times, the association of certain sights with other feelings—of softness or hardness, thickness or thinness—provide a reservoir of intuition about what the video from the RASD is showing. One can think of adapting to a surgical RASD as the development of skills somewhat like those required in a videogame console control—so that just as the flick of a trigger on a joystick could result in a kick for a player’s avatar in a game, so too can a small movement in the Da Vinci console cause a cut or lift a vein. Moreover, as video proliferates, the “second nature” of the screen may become a “first nature” for trainees, and a source of data for machine learning programs to identify past errors and deter future ones.

According to some critics of health technology, the dissemination of RASDs is yet another tale of healthcare spending gone out of control. The devices can cost over \$1 million, with high upkeep and maintenance

fees.¹⁰ Surgeons must invest valuable time to learn the ins and outs of the new system. Some have questioned the value of the technology.¹¹

But it is important to take this early medical evidence with a grain of salt. One key problem emerges in many areas of clinical innovation—those completing robotic surgeries in the first decade of studies could only have had 5 to 10 years of experience using the robot, since it was so new, while their output was sometimes being compared to the surgeries of those who had perfected their skills in open prostatectomies for decades. Outcome measures can also be unfairly narrow. For example, according to some accounts, those who undergo a robotic surgery for prostate cancer can often return home after just four days at the hospital, while those undergoing open prostatectomies often take six or seven days. In the case of kidney cancer, the smaller incision used for robotic surgeries can lead to less pain and shorter recovery times. Surgeons who use the RASDs tend to agree that the tools make surgery much easier than pure manual manipulation. The human hand has not evolved to manipulate a scalpel to make fine distinctions between healthy and cancerous tissue; surgical robots can be specifically designed to take on

¹⁰ Cameron Scott, *Is da Vinci Robotic Surgery a Revolution or a Rip-off?*, HEALTHLINE (Aug. 10, 2016), <https://www.healthline.com/health-news/is-da-vinci-robotic-surgery-revolution-or-ripoff-021215>.

¹¹ See Michelle Andrews, *Gynecologists Question Use of Robotic Surgery For Hysterectomies*, NPR (Apr. 23, 2013), <http://www.npr.org/blogs/health/2013/04/23/178576759/gynecologists-question-use-of-robotic-surgery-for-hysterectomies>; see also *Statement on Robotic Surgery by ACOG President James T. Breeden, MD*, DR. WHITTED (Mar. 14, 2013), <http://drwhitted.net/statement-on-robotic-surgery>; *Hospitals Misleading Patients About Benefits of Robotic Surgery, Study Suggests*, JOHNS HOPKINS MED. (May 18, 2011), http://www.hopkinsmedicine.org/news/media/releases/hospitals_misleading_patients_about_benefits_of_robotic_surgery_study_suggests; *Robotic Surgery: More Complications, Higher Expense for Some Conditions*, COLUM. U. IRVING MED. CTR. (Oct. 8, 2014), <http://newsroom.cumc.columbia.edu/blog/2014/10/08/robotic-surgery-complications-higher-expense-conditions/>.

this task. Videorecording via miniaturized cameras may also enable new research on body tissue. This recording already helps speed the diffusion of surgical innovations, as doctors share videos of particularly successful surgical techniques at medical conferences.

Complementary robotics are dominant now. To promote its regulatory agenda in the area of robotic surgery in 2015, the Food and Drug Administration (FDA) announced a public workshop on RASDs.¹² Speakers included cutting edge physicians and firms. Neither actual implementations of, nor planned development of, fully autonomous surgical devices were high on the agenda. Admittedly, firms planning fully autonomous systems may be in stealth mode—they could lose current surgeons as clients if they talked too openly about replacing them. And in 2016, a stitching robot did mark one notable exception to this pattern.¹³ While acknowledging that “the current paradigm of robot-assisted surgeries (RASs) depends entirely on an individual surgeon’s manual capability,” inventors demonstrated that a robot could stitch a split pig intestine together, besting the performance of human surgeons. Billed as the “first autonomous robot” to operate, it managed to bind a hole in soft tissue with speed and precision. The question, now, is whether further industrial development in this area should try to *change* the dominant trend in robotics, by replacing human surgeons—or

12 *Public Workshop—Robotically-Assisted Surgical Devices: Challenges and Opportunities*, July 27-28, 2015, U.S. FOOD & DRUG ADMIN. (2015), <http://wayback.archive-it.org/7993/20170112084805/http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm435255.htm>.

13 See Azad Shademan et al., *Supervised Autonomous Robotic Soft Tissue Surgery*, 8 SCI. TRANSLATIONAL MED. 337ra64 (2016); Beth Mole, *First Autonomous Robot to Operate on Soft Tissue Outdoes Human Surgeons*, ARS TECHNICA (May 6, 2016), <http://arstechnica.com/science/2016/05/smart-sewing-machine-nails-worlds-first-autonomous-soft-tissue-surgery>.

if the present path of human-computer interaction is something to maintain.

In theory, it would seem obvious that a robot with minuscule, nimble, even laparoscopic probes would be a better interventionist than the average surgeon—and perhaps, eventually, even the best ones. “We rely on the dexterity of human surgeons but now we know machines are quite a bit more precise than humans. If you want to do things with extreme precision, a machine would be better,” said one Google researcher.¹⁴ And if the “Smart Tissue Autonomous Robot (STAR) could sew more evenly and consistently than even an experienced surgeon” on a pig intestine, there is no reason in principle it could not do the same with human flesh.¹⁵ However, “STAR was still dependent on a surgeon to make the initial incision, take out the bowel, and line up the pieces” before it began suturing.¹⁶ As leading health technology scholars observed in a review article, it will likely be many years or decades until fully autonomous robots take on a surgery from start to finish.¹⁷

14 Mark Harris, *Founder of Google’s Stealthy Surgical Robotics Project Speaks*, WIRED (Dec. 14, 2015), <https://backchannel.com/founder-of-google-s-stealthy-surgical-robotics-project-speaks-c2f7e0dfe13c#.8brbf1co>.

15 James Vincent, *A Robot Surgeon Has Passed a Major Milestone—Sewing up Pig Guts*, THE VERGE (May 4, 2016), <https://www.theverge.com/2016/5/4/11591024/robot-surgery-autonomous-smart-tissue-star-system/>.

16 *Id.* The STAR system has advanced since 2016, according to a recent study, whose authors claim that “Although the system does require manual fine adjustment of the robot to correct positioning if a stitch is missed, more than 83% of the suturing task is completed autonomously using this workflow.” Hamed Saeidi et al., *Autonomous Robotic Laparoscopic Surgery for Intestinal Anastomosis*, 7 SCI. ROBOTICS eabj2908, at 2 (2022). However, it still involves a human operator, who “selects among autonomously suggested suture plans or approves a replanning step and monitors the robot for repeating a stitch as needed.” *Id.*

17 Drew Simshaw et al., *Regulating Healthcare Robots: Maximizing Opportunities While Minimizing Risks*, 22 RICH. J.L. & TECH. 1, 3 (2016) (“Such autonomy includes the supervisory control paradigm, in which certain functions are automated with a

Direct-to-consumer medical automation and robotics is currently not a plausible step forward in many areas. First, scientific evidence is often extremely difficult for the layman to interpret. Large corporations can and often do market products in unscrupulous ways. Large pharmaceutical firms and device manufacturers have systematically skewed data to support their products.¹⁸ Responsibility for harms is also often defused or deflected.¹⁹ Information is scattered, and those untrained in medicine may not be able to interpret conflicting studies. Uncomplicated medical devices, like joint replacements and screws, have continued to be implanted in patients years after serious safety concerns were raised. Moreover, firms may impose on individuals “hold harmless” clauses, preventing future lawsuits.²⁰ In other words, even in a field as technical and, in principle, automatable as surgery, it is vital to

human supervising the system, all the way to **fully autonomous robots**. Similarly, health care environments that are reliant on or dominated by all-purpose ‘healthcare companions’ and robotic ‘doctors,’ utilizing artificial intelligence, will raise fascinating questions. However, these technologies **will not be available for purchase or be deployed in our hospitals any time soon.**”).

- 18 Frank Pasquale, *Grand Bargains for Big Data: The Emerging Law of Health Information*, 72 MD. L. REV. 682, 689 (2013) (“This massive misallocation of resources may be attributed, in part, to failures to act on current data, but it also occurs because useful data is not available, does not exist, or is actively hidden.”); BEN GOLDACRE, *BAD PHARMA: HOW DRUG COMPANIES MISLEAD DOCTORS AND HARM PATIENTS* 27 (2013) (“First, as we saw in the case of reboxetine, **doctors and patients are misled about the effects of the medicines they use**, and can end up making decisions that cause avoidable suffering, or even death.”); *see also* JEANNE LENZER, *THE DANGER WITHIN US: AMERICA’S UNTESTED, UNREGULATED MEDICAL DEVICE INDUSTRY AND ONE MAN’S BATTLE TO SURVIVE IT* (2017).
- 19 Anita Bernstein, *(Almost) No Bad Drugs: Near-Total Products Liability Immunity for Pharmaceuticals Explained*, 77 WASH. & LEE L. REV. 3, 8 (2020). “Modern products liability identifies three categories of product defect; **courts insulate drug manufacturers from responsibility for all three.**”
- 20 MARGARET JANE RADIN, *BOILERPLATE: THE FINE PRINT, VANISHING RIGHTS, AND THE RULE OF LAW* 199 (2012). “In the case of a [technological protection measures (TPMs)], the curtailing of user rights is much more literally a part of a digital product than is a set of boilerplate terms that comes with a physical product or a service.”

keep some person in the loop as a source of information and advice for laypeople. MIT economist David Autor offers a general reality check about automation that applies with even more force here:

Most automated systems lack flexibility—they are brittle. Modern automobile plants, for example, employ industrial robots to install windshields on new vehicles as they move through the assembly line. But aftermarket windshield replacement companies employ technicians, not robots, to install replacement windshields. Why not robots? Because removing a broken windshield, preparing the windshield frame to accept a replacement, and fitting a replacement into that frame demand far more real-time adaptability than any contemporary robot can approach.²¹

Of course, futurists can probably imagine a robot in a self-driving car that can navigate itself to your car, drive it to a garage, and order other robots to replace the windshield. But even that scenario depends on a chain of contingencies and potential human interventions when things go wrong. When the stakes are higher—for instance, replacing a kidney instead of a windshield—then even more back-up systems and planning will be necessary.

To be sure, even in situations where a human health care provider is fully in charge, there is some level of responsibility, and perhaps even agency, in AI tools used. Bruno Latour puts the matter starkly, claiming that “any thing that does modify a state of affairs by making a difference

²¹ David Autor, *Polanyi's Paradox and the Shape of Employment Growth* 31 (Nat'l Bureau of Econ. Res. Working Paper No. 20485, 2014), <http://www.nber.org/papers/w20485>.

is an actor.”²² He concedes that “it is hard to see how a hammer, a basket, a door closer, a cat, a rug, a mug, a list, or a tag could act.”²³ However, as one of his more insightful reviewers observes:

Contrary to some caricatures, actor-network approaches do not fight sociology by proclaiming a contrary religion in which objects and scallops are mysteriously endowed with agency: they simply refuse to ignore, *a priori*, large realms of activity. Close empirical observation—and not only ethnography, incidentally—may reveal that objects, animals, plants, theories, chemicals, texts, and people may be jostling and pushing in ways that escape observers who already know that the truth lies under the facts, in fields, class structure, etc. What is or is not an actor is a matter for empirical investigation; there is no general theory.²⁴

A similar resistance to a totally generalized theory of tort liability is evident in U.S. doctrine, in ways that lend some credence to actor-network-driven approaches in law. For example, a leading case promoting a national (rather than local) and unitary (rather than tiered) standard of care in malpractice, also recognized a “resource-based caveat:” a doctor in a resource-constrained setting cannot be expected to meet a standard of care established in a more resource-supplied locale.²⁵ Thus medical equipment in such a case may be considered

22 BRUNO LATOUR, REASSEMBLING THE SOCIAL: AN INTRODUCTION TO ACTOR-NETWORK-THEORY 71 (2005).

23 *Id.*

24 Mariana Valverde, *Reassembling the Social: An Introduction to Actor-Network Theory. By Bruno Latour*, 41 LAW & SOC’Y REV. 744, 745 (2007) (reviewing BRUNO LATOUR, REASSEMBLING THE SOCIAL: AN INTRODUCTION TO ACTOR-NETWORK-THEORY (2005)).

25 *Hall v. Hilbun*, 466 So.2d 856 (1985).

something of an actant in the court's conceptualization of medical responsibility. Similarly, the development of theories of enterprise liability in health care indicate a level of responsibility for outcomes to a non-human "person," the corporation. Nevertheless, the distinction between a (still-putative) robotic surgeon, and a robotic tool operated by a person, is clear. Even if the tool acquires sophisticated sensing and clinical decision support capabilities, it is ultimately aiding a person in a task, rather than completing the task itself.

Even profit-minded robotics manufacturers may want to keep human beings "in the loop"—both to assure better use of their products, and to deflect liability. Legal reform will be needed to avoid opportunism built around excessively deflective doctrines. If something goes wrong with a mechanical system—be it an autopilot on a plane or a device used in surgery—doctrines of "competent human intervention," "the learned intermediary," or "captain of the ship" have tended to shift liability to the person operating (or merely capable of taking control from) the device, rather than the device maker.²⁶ But even when robotics and AI only complement a professional, there still need to be opportunities for plaintiffs and courts to discover whether the technology's developers and vendors acted reasonably. Such inquiry is endangered by expansive interpretations of the above doctrines.²⁷ As

26 Madeleine Elish & Tim Hwang, *Praise the Machine! Punish the Human! The Contradictory History of Accountability in Automated Aviation* 7, 21 (Data & Soc'y Res. Inst. Working Paper No. 1, 2015) (on captain of the ship and the learned intermediary respectively); Sharona Hoffman & Andy Podgurski, *Finding a Cure: The Case for Regulation and Oversight of Electronic Health Record Systems*, 22 HARV. J.L. & TECH. 103, 133 (2008) (on competent human intervention).

27 The learned intermediary doctrine holds that the manufacturer of a new technology "discharges their duty of care to consumers by providing adequate warnings" about its potential for harm to professionals using the technology. James Nelson, *Arizona High*

the example of the tendon-cutting device showed, all responsibility for an error should not rest on a doctor when complementary robotics fails to accomplish what it promised to do. To hold otherwise would again be an open invitation to technologists to rest on their laurels.²⁸

Even if technologists develop fully autonomous robot surgeons, the ultimate “backup system” would be a skilled human surgeon with some experience, flexibility, and creativity.²⁹ Our aim should not be to replace such individuals, but to aid in their efficiency and effectiveness. The sequence and shape of automation in health care cannot simply be dictated from on high by engineers. Rather, domain experts need to be consulted, and they need to buy into a larger vision of progress in their field. Perhaps more of medicine should indeed be automated—but law should help ensure that physicians themselves are lasting partners in that process. They should be helped, not replaced, by machines, for the short to medium term.

Of course, in the long term, new arrangements may arise. The distinction between complementary and substitutive robotics may become more a difference of degree rather than kind in some routinized aspects of medical practice. The right tools make a job easier—and at

Court Reestablishes the “Learned Intermediary” Doctrine, A.B.A. (Feb. 25, 2016), <https://www.americanbar.org/groups/litigation/committees/mass-torts/practice/2016/learned-intermediary-doctrine>.

28 Aaron S. Kesselheim, *Permitting Product Liability Litigation for FDA-Approved Drugs and Devices Promotes Patient Safety*, 87 *CLINICAL PHARMACOLOGY & THERAPEUTICS* 645, 645 (2010). Note that both physicians and technologists may share responsibility for preventable errors. The amount of compensation in both negligence and strict liability regimes may be limited by state legislatures to avoid over-detering innovation. But compensation is still due.

29 NICHOLAS CARR, *THE GLASS CAGE: HOW OUR COMPUTERS ARE CHANGING US* 155 (2015).

times even more engaging. An analogy from the use of technology in driving is useful. A truck driver may find that cruise control frees his foot from the gas pedal. Automatic transmission makes it easier to shift from high to low gear. Collision avoidance software can warn him about cars in his blind spot.³⁰ Technology can make the job much easier—until it replaces the driver altogether. So, there is delicate balance between inventions that help workers and those which replace them altogether. Economists tend to call the former “complementary” to labor, and the latter “substitutive.”

The “be careful what you wish for” story of a worker gradually replaced by his tools has a long history. Aristotle speculated about the effects of self-driving looms centuries before they transformed manufacturing.³¹ Hegel tells the story of a master who gradually becomes weaker and less competent in comparison with a slave whom he forces to perform ever more tasks. Labor economists have worried that “deskilling” is the natural consequence of a more mechanized workplace, paving the way to mass automation.³²

However, a smooth transition from “being helped” to “being replaced” by technology is not an inevitability. Nor should it be in

30 Karen E. C. Levy, *The Contexts of Control: Information, Power, and Truck-Driving Work*, 31 INFO. SOC’Y 160, 166 (2015); NAT’L HIGHWAY TRAFFIC SAFETY ADMIN., ACCELERATING THE NEXT REVOLUTION IN ROADWAY SAFETY 2-3 (2016), https://www.transportation.gov/sites/dot.gov/files/docs/DOT_AV_Policy.pdf.

31 ARISTOTLE, POLITICS 1-18 (Benjamin Jowett trans., Indo-European Publishing 2012) (350 B.C.E.) (if “shuttles wove and picks played kitharas [stringed instruments] by themselves, master-craftsmen would have no need of assistants and masters no need of slaves.”).

32 HARRY BRAVERMAN, LABOR AND MONOPOLY CAPITAL: THE DEGRADATION OF WORK IN THE TWENTIETH CENTURY, at xiii (1974); CLAUDIA GOLDIN & LAWRENCE F. KATZ, THE RACE BETWEEN EDUCATION AND TECHNOLOGY 2 (2008).

medicine. While fields like driving have a relatively simple goal (getting to a destination as quickly and safely as possible), much of medicine entails difficult and subtle trade-offs. There is a much better case for aspiring to build drivers' skills into autonomous vehicles, than trying to do the same for physicians.³³ Whereas the relevant data about autonomous cars will be relatively transparent to potential buyers, performance data for autonomous medical equipment is likely to be more opaque and contested.³⁴ For that reason alone, keeping a “human in the loop” is critical. When there are complicated value judgments at stake (for example, whether to try a riskier or experimental knee surgery in order to try to increase the patient's ability to run afterwards), there are all manner of trade-offs that demand a skilled and experienced domain expert's attention.

III. Strict Liability for Substitutive Automation

Insurance contracts, licensure, and certification rules have a powerful impact on technological development.³⁵ There is no autonomous robotic surgeon today—only “robotically assistive surgical devices.” Even if some genius were to invent a fully autonomous surgical machine, it would need to be vetted by years of tests and

³³ Moreover, even in the realm of driving, some firms are focused on keeping human beings in the picture. For example, Toyota has promoted cars with a spectrum of machine involvement, from chauffeur mode (which requires minimal monitoring by a driver) to guardian mode (which focuses the car's computing systems on accident avoidance, while a person helms the vehicle). Planes have had autopilot capacities for decades, but commercial carriers still tend to have at least two persons at the helm.

³⁴ GOLDACRE, *supra* note 18, at 12.

³⁵ Meghan Hamilton-Piercy, *Cybersurgery: Why the United States Should Embrace This Emerging Technology*, 7 J. HIGH TECH. L. 203, 216 (2007).

research before mass adoption occurred.³⁶ Reimbursement rules may create another hurdle for rapid adoption of robotics. When robots generate marginally better outcomes, public and private insurers will think twice about paying high fees to guarantee access to them.

Liability concerns will also slow the development of autonomous systems. For example, anesthesia may seem like the ideal use case for an autonomous robot, since machine-readable reports of bodily states may, in principle, be able to indicate any untoward development meriting an intervention. However, the field still seems to be focused on assistive models. The Sedasys anesthesia machine, for instance, was licensed by the FDA to assist anesthesiologists in relatively straightforward operations.³⁷ It could monitor patients' breathing and heart rate, administer set doses of anesthesia, and alter those doses in response to new data.³⁸ Like the "guardian" mode of cars, designed to prevent accidents, Sedasys robots could spot warning signs of adverse events in advance of their actually occurring.

The FDA observed that Sedasys's technology might lay the foundations for higher levels of technological intervention in anesthesiology:

36 Margo Goldberg, *The Robotic Arm Went Crazy! The Problem of Establishing Liability in A Monopolized Field*, 38 RUTGERS COMPUTER & TECH. L.J. 225, 250 (2012).

37 U.S. FOOD & DRUG ADMIN., SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) 38 (2013), https://www.accessdata.fda.gov/cdrh_docs/pdf8/p080009b.pdf.

38 PAUL G. BARASH ET AL., CLINICAL ANESTHESIA 1291 (8th ed. 2017) ("In May 2013, the FDA approved Sedasys, a computer-assisted patient-controlled sedation system that administers propofol for colonoscopies/endoscopies. Patients are monitored with electrocardiography, pulse oximetry, noninvasive blood pressure monitoring, and end-tidal carbon dioxide. Sedation is also further monitored via an earpiece through which the computer tells the patient to squeeze a handset. Based on these parameters, Sedasys will algorithmically adjust the infusion rate of propofol.").

The approval of the SEDASYS System represents a notable advancement in the field of semi-autonomous control of drug administration in medicine. The device utilizes negative feedback from specialized physiological monitors to assess and limit drug dosing and thereby control the depth of sedation. The principle of negative feedback control may be applicable to a variety of drugs and clinical scenarios different from those associated with sedation management.³⁹

However, the agency also stated that “the use of the device is restricted to settings where a practitioner trained in the administration of general anesthesia is immediately available to the user for assistance or consultation as needed. Immediate availability in this context means that an anesthesia professional will be available on site to respond to an emergency situation.”⁴⁰ This type of safeguard both reflects and complicates the larger argument of this article that human control or monitoring should be required no matter how autonomous the robotic system. While the core case of complementarity is a physician directly operating or supervising the relevant medical AI and robotics, a secondary application of the concept may include a physician (here, an anesthesiologist) maintaining presence in case of complications, or taking over upon notice of complications.⁴¹

There are many possible future developments for such anesthesia technology. In Europe, national health authorities will be pulled in opposing directions. Health cost cutters may favor full robotization as a

³⁹ U.S. FOOD & DRUG ADMIN., *supra* note 37, at 37.

⁴⁰ *Id.* at 38.

⁴¹ BARASH ET AL., *supra* note 38, at 1291; Basavana G. Goudra & Preet M. Singh, *SEDASYS, Sedation, and the Unknown*, 26 J. CLINICAL ANESTHESIA 334, 335 (2014).

cost-cutting measure. On the other hand, European workers have, in general, been able to play a larger role in the deployment of technology than their American peers. That trend would encourage a slow roll-out of the devices, as they gradually proved their worth, and health care workers (including anesthesiologists and nurse-anesthetists) transitioned toward positions monitoring and improving the machines—or migrated toward jobs still requiring the “human touch.”

In the US, there are also conflicting political and economic currents. In the country with the highest health care expenditures on the planet, costs are always a concern. But risk-averse hospitals may only permit patients to opt for cheaper, robotic anesthesiology if they waive liability, promising not to sue the hospital if something goes wrong—and may ultimately find such a waiver unenforceable.⁴² The dubious legal status of such waivers in the past has cast a long shadow over advocacy of “consumer directed health care” in the United States.⁴³ While some doctors wanted to give patients the option of “last year’s medicine at last year’s prices,” they did not want to be sued for malpractice if the cheaper option proved ineffective. Similar concerns will arise as device makers market robotic systems for hospitals and doctors’ offices.

⁴² For an influential discussion of general waivers of liability in a medical context, see *Tunkl v. Regents of the Univ. of Cal.*, 383 P.2d 441 (Cal. 1963) (disallowing waivers of liability); *but see Colton v. N.Y. Hosp.*, 414 N.Y.S.2d 866 (1979) (upholding exculpatory clause in a case where an experimental treatment was the only option for the patient).

⁴³ Matthew J.B. Lawrence, *In Search of an Enforceable Medical Malpractice Exculpatory Agreement: Introducing Confidential Contracts as a Solution to the Doctor-Patient Relationship Problem*, 84 N.Y.U. L. REV. 850, 856 n.20 (2009) (noting that “courts typically disfavor exculpatory agreements in the healthcare context,” in the context of a larger examination of scholarly efforts to advocate for a different approach with respect to consumer-directed health care.).

Assume, for now, that such disclaimers and exculpatory clauses prove ineffective. What would be the proper liability regime for a fully autonomous anesthesia machine? Assume for purposes of this article that the machine's operations were not explicable to the surgeons and other medical personnel among whom it was deployed—so that there is no sense in which it could be considered merely “helping” them.⁴⁴ What is the proper way to the responsibility of designers, manufacturers, vendors, and users of such a machine for preventable adverse outcomes?

In a jurisdiction where human anesthesiologists are widely available, strict liability may turn out to be a compelling approach with respect to designers, given compelling scholarship on other, similar design scenarios.⁴⁵ A negligence regime risks undermining proper levels of accountability.⁴⁶ Consider, for instance, a machine that fails to

44 On the critical distinction between explainable and non-explainable AI in medical automation and robotics, see Barbara J. Evans & Frank Pasquale, *Product Liability Suits for FDA-Regulated AI/ML Software*, in *THE FUTURE OF MEDICAL DEVICE REGULATION: INNOVATION AND PROTECTION* 22, 26-27 (I. Glenn Cohen et al. eds., 2022).

45 For an example of such scholarship, see Eric Lindenfeld, *3D Printing of Medical Devices: CAD Designers as the Most Realistic Target for Strict, Product Liability Lawsuits*, 85 *UMKC L. REV.* 79, 98-100 (2016). Lindenfeld argues that “[s]trict [l]iability for CAD [d]esigners [w]ould [n]ot be a [b]ig [l]eap for the [c]ourts.” *Id.* at 98. One reason for this is that “while most courts refrain from finding architects and engineers strictly liable, there is at least some authority which suggests that those engaged in design related services could be considered ‘sellers’ as opposed to ‘service providers’ under the Second Restatement.” *Id.* at 99.

46 Joseph L. Reutiman, *Defective Information: Should Information Be a “Product” Subject to Products Liability Claims?*, 22 *CORNELL J.L. & PUB. POL’Y* 181, 187 (2012) (“Proving negligence can be an impossible proposition in certain cases where evidence has been destroyed because of the product defect itself or misfeasance on the part of the defendant and can potentially result in the complete denial of recovery.”). There are also many troubling ways to shift blame in the complex relationships between medical professionals, hospitals, vendors of AI, and others in the distribution chain—particularly given “hold harmless” clauses or other exculpatory contract terms that may be foisted on providers. Frank Pasquale, *Six Horsemen of Irresponsibility*, 79

include data about certain vulnerable groups. If persons in such groups are harmed because of such a lack of data, they may not be able to recover damages under negligence standards, since the device's vendor may claim (if there is adequate statistical evidence) that the device met the standard of care for the physicians it replaced. By contrast, strict liability requires vendors of substitutive AI and robotics to anticipate and correct such predictable defects, and to invest in monitoring for and anticipating less predictable errors. Note, too, that strict liability does not require a vendor of substitutive AI to be "perfect." Expected damages will be balanced against expected profits. To the extent a strict liability standard appears to be undermining valuable innovation, limits on damages can temper the potential unfairness of liability without fault.⁴⁷ Just as they do with respect to malpractice exposure, insurers may offer liability insurance to assist innovators in risk-shifting. And if the substitutive AI has a performance record clearly as good as, or better than, the extant standard of care (be that unaided human care, or, more likely, human-machine cooperation), policymakers should step in to pay damages out of the public fisc, or to provide cheap insurance against such damages to vendors of substitutive AI and others potentially held liable under a strict liability standard.⁴⁸

MD. L. REV. 105, 109-13 (2019) (discussing mutually reinforcing strategies of liability-deflection).

⁴⁷ By contrast, if the extant performance standards are much better than those of substitutive automation, the significant damages available pursuant to strict liability for substitutive automation will be a critical prod toward the restoration of a unitary standard of care.

⁴⁸ Strict liability could also transition into a no-fault compensation scheme like the US's National Vaccine Injury Compensation Program (NVICP), which compensates those who have suffered side effects from vaccinations. *See, e.g.,* Frances E. Zollers et al., *No More Soft Landings for Software: Liability for Defects in an Industry That Has Come of Age*, 21 SANTA CLARA COMPUTER & HIGH TECH. L.J. 745, 773 (2005) ("we favor an approach that accepts strict product liability for software and lets the case

However, the definition of “as good, or better” performance records needs to be granular, so as to be sensitive to historical victims of health disparities. There has been growing concern that the data used for diagnostic AI may not adequately represent all groups in society. For example, minority groups may be poorly represented in databases.⁴⁹ Women are seriously disadvantaged as well.⁵⁰ Diagnostic AI that ignores all these problems, and which still generally delivers better results than unaided human observation, may not be actionable under a negligence standard for those it fails to help—particularly if the standard of care is unaided human observation. However, under a strict liability standard, failure to include available, more representative databases, that leads to preventable accidents, would leave vendors liable for adverse events even if they managed to do better on average than the standard of care. Such liability may be critical to incentivizing them to address health disparities.

Efthimios Parasidis has convincingly argued that courts need to recognize and counteract automation bias—that is, the tendency of persons to assume without proper evidence that a machine has better

law find the point of maximum social benefit through the application of a rigorous cost/benefit analysis. In the rare case where a beneficial software product is being kept out of the market because of liability concerns and that claim is corroborated, there are a number of public policy strategies that can be employed in mitigation. For example, there is federal legislation limiting vaccine manufacturers’ liability for certain vaccines.”). The NVICP is funded by an excise tax on each vaccine dose.

⁴⁹ See Adewole S. Adamson & Avery Smith, *Machine Learning and Health Care Disparities in Dermatology*, 154 JAMA DERMATOLOGY 1247 (2018). This lack of diversity also afflicts genomics research. Non-European groups tend not to be as well-represented in DNA databases as European groups. Alice B. Popejoy et al., *The Clinical Imperative for Inclusivity: Race, Ethnicity, and Ancestry (REA) in Genomics*, 39 HUM. MUTATION 1713, 1717-18 (2018).

⁵⁰ See CAROLINE CRIADO PEREZ, *INVISIBLE WOMEN: DATA BIAS IN A WORLD DESIGNED FOR MEN* (2019).

judgment than persons.⁵¹ The problem of automation bias is recurrent and is a persistent temptation when often-overworked professionals seek tools to ease their workload. More stringent liability standards are a way of gradually ensuring a lower risk level in the industry.⁵²

A vehicle manufacturer may be held responsible for an accident if the manufacturer failed to design or manufacture the vehicle properly. Similarly, AI and robotics may be designed or developed in a way that fails to conform to basic standards of safety and reliability. The product analogy increases accountability for safety, reliability, and security.⁵³ Unpredictability of advanced AI systems means that forms of accountability reflecting classic legal standards are critical. For example, those keeping particularly vicious or wild animals (like lions and tigers)

⁵¹ See Efthimios Parasidis, *Clinical Decision Support: Elements of a Sensible Legal Framework*, 20 J. HEALTH CARE L. & POL'Y 183, 225 (2018) (“As to the coding phase of software development, a strong argument can be made that coding should be encompassed under the category of manufacturing defects [and this is critical because U.S. courts typically employ strict or product liability analysis for manufacturing defects]... [A]llowing products liability claims for CDS systems also may be a way to counter disclaimers of liability that typically are found in CDS contracts.”) See also Kevin R. Pinkney, *Putting Blame Where Blame is Due: Software Manufacturer and Customer Liability for Security-Related Software Failure*, 13 ALB. L.J. SCI. & TECH. 43, 51-62 (2002) (focusing on security-related failures); Michael D. Scott, *Tort Liability for Vendors of Insecure Software: Has the Time Finally Come?*, 67 MD. L. REV. 425, 469-70 (2008).

⁵² Zollers et al., *supra* note 48, at 768-73.

⁵³ However, as Jamil Ammar warns, “From the perspective of product liability, courts in the U.S. consider computer software to be a service rather than a product. To date, courts have been reluctant to extend theories of product liability to software.” Jamil Ammar, *Defective Computer-Aided Design Software Liability in 3D Bioprinted Human Organ Equivalents*, 35 SANTA CLARA HIGH TECH. L.J. 37, 40 (2019). One purpose of this article is to urge courts (both in the U.S. and elsewhere) to reconsider this approach in the context of substitutive AI in medicine, particularly given its integration of software into complex sociotechnical apparatuses that include persons, hardware, and data.

are strictly liable if these beasts escape and cause harm.⁵⁴ Enterprise liability “asserts that actors should bear the costs of those accidents that are characteristic of their activities and then distribute those costs among all those who benefit from the imposition of the risks at issue.”⁵⁵ Professor Danielle Keats Citron inventively applied these ideas to the digital age by analogizing massive data holdings to early water reservoirs which, if breached, could cause death and destruction to communities immediately adjacent to them.⁵⁶ Much the same could be said of autonomous robotics or AI in critical medical situations when an irresponsible user decides to simply let them run autonomously. When they are marketed or developed to be used in autonomous mode, their developers and vendors must take responsibility. AI and robotics systems are ultimately attributable to humans.⁵⁷

A strict liability standard will be controversial. The legal scholar Ryan Abbott has argued that, if an autonomous vehicle is, in general, safer than the typical human driver, only a negligence cause of action should be available.⁵⁸ If accepted, such a comparison would make negligence, rather than strict or product liability, the proper judicial

54 Animals Act 1971, c. 22, § 2(1) (Eng.); RESTATEMENT (THIRD) OF TORTS: PHYS. & EMOT. HARM § 22 WILD ANIMALS (AM. L. INST. 2023).

55 Gregory Keating, *The Theory of Enterprise Liability and Common Law Strict Liability*, 54 VAND. L. REV. 1285, 1334 (2001).

56 See Danielle Keats Citron, *Reservoirs of Danger: The Evolution of Public and Private Law at the Dawn of the Information Age*, 80 S. CAL. L. REV. 241 (2007).

57 And they should be kept that way. PASQUALE, *supra* note 8, at 109 (proposing a fourth law of robotics requiring all AI and robotics to be attributable to responsible persons).

58 Ryan Abbott, *The Reasonable Computer: Disrupting the Paradigm of Tort Liability*, 86 GEO. WASH. L. REV. 1, 1 (2018) (“Under current legal frameworks, suppliers of computer tortfeasors are likely strictly responsible for their harms. This Article argues that where a supplier can show that an autonomous computer, robot, or machine is safer than a reasonable person, the supplier should be liable in negligence rather than strict liability.”).

response to errors. For Abbott, the standard of a “reasonable computer” would then supplant that of the “reasonable person,” in judicial considerations of the type and level of responsibility to assign. Such an approach would help ensure that there are not undue impediments to the development of autonomous vehicles. However, it is likely less appropriate in the medical field, since health care providers are likely to be far more valuable in guiding the deployment of technology, long-term, than “guardian drivers” who have been deployed to restrain self-driving cars when they errantly threaten to crash into a person or another vehicle. That ongoing need for guidance and development by present, expert, professionals counsels in favor of a strict liability standard in the case of substitutive automation in medicine, to promote ongoing complementarity.

There are other problematic dimensions of a “reasonable computer” standard. As Jacob Turner argues in his book *Robot Rules*, a negligence standard may be very difficult to apply here, because “[a] reasonable human person is fairly easy to imagine. The law’s ability to set an objective standard of behaviour takes as its starting point the idea that all humans are similar... AI, on the other hand, is heterogeneous in nature: there are many different techniques for creating AI and the variety is likely only to increase in the future as new technologies are developed.”⁵⁹ This is a valuable reminder of the plasticity of the mechanical world, at least relative to that of humans.⁶⁰

⁵⁹ JACOB TURNER, *ROBOT RULES* 90 (2019).

⁶⁰ Any attribution of robot interests or rights based on analogy to humans, for instance, is incoherent because the very conceptions of well-being or desire that are the foundation of such rights and interests may be reprogrammed in the robot. Such “reprogramming” is, by contrast, exceptionally difficult and damaging when undertaken with respect to a person, if it can be done at all. Given the limited advances made toward robotics, we must turn to fiction to see an illustration of this point. The television series *Westworld* tried to attribute something like the human fixity I have

It is not unreasonable for persons to expect that AIs unleashed upon the world will have some basic rules of engagement, such as being programmed and designed to limit human harm. This ethical principle was articulated as the first of Isaac Asimov's Laws of Robotics and shows up in various forms in many other works on human-machine interaction.⁶¹ Strict liability for autonomous machines and AI is one more way to ensure that prevention of harm is prioritized.

IV. Concluding Remarks: Virtues of a Mixed Negligence-Strict Liability Regime

While promoting AI as a substitute for competent medical personnel, some firms will fail to engage in the quality control and other steps necessary to avoid disastrous outcomes. Tort lawsuits will follow, with plaintiffs demanding damages for the firms' failures to meet the relevant standard of care. Legislators and courts will need to develop approaches to liability adequate to the new technological environment. As they do so, they will effectively set nuanced and contextualized standards for the deployment of AI. Distinguishing between complementary and substitutive AI is one conceptual tool that will help them do so.

described in its episodes featuring the mental breakdown of the robot Teddy after he was reprogrammed to be hard-hearted and violent by the series' protagonist, Delores. However, the depiction is unconvincing because the original programming connecting breakdown to personality trait discordance could itself have been reprogrammed.

⁶¹ See ISAAC ASIMOV, I, *ROBOT* (1950); Colin P.A. Jones, *Robot Rights: From Asimov to Tezuka*, JAPAN TIMES (Mar. 6, 2019), <https://www.japantimes.co.jp/community/2019/03/06/issues/robot-rights-asimov-tezuka>.

When AI or robotics simply assist a professional, they are tools. In medicine, the doctrine of “competent human intervention” has shifted liability away from those who make devices and toward the professionals who use them. However, the professional in such scenarios should not bear the entire burden of responsibility. His or her tools can be produced well or badly, and vendors of defective, complementary AI and robotics should be held responsible for negligence. Both legislators and courts will need to develop standards of care designed to incentivize proper safety, security, and risk avoidance. But the burden of proof will be on the plaintiff to demonstrate that not only a skilled medical professional, but also the maker of the tools used by such a professional, should be held liable for a preventable adverse outcome.

When AI and robotics replace a skilled medical professional, the burden shifts. The vendor of such computational systems needs to take on the responsibility for errors and accidents. At the damages phase of litigation, the vendor may explain how its damages should be mitigated based on its AI’s performance relative to the extant human or human-machine based standard of care. Such responsibility for explanation will serve an important information-forcing function in areas where public understanding is often limited by trade secrecy.⁶²

Accountability is a contested and complex concept in tort law. It is all too easy to reduce the problem of preventable adverse events in medicine as a simple matter of providers’ responsibility to patients. However, a broader political economy perspective goes beyond the dyad

⁶² For another example of information-forcing regulation, see Frank Pasquale, *Ending the Specialty Hospital Wars: A Plea for Pilot Programs as Information-Forcing Regulatory Design*, in *THE FRAGMENTATION OF U.S. HEALTH CARE: CAUSES AND SOLUTIONS* 235 (Einer Elhauge ed., 2010).

of provider-patient, incorporating larger concerns about the nature of the labor force, the explainability of AI, and the power of dominant technology firms.⁶³ As AI and robotics take on more roles, there will be cost pressures for technology to prematurely replace providers. Strict or enterprise liability for such adverse events arising out of particular replacements will generally help deter its happening too quickly. By ensuring that vendors of medical AI and robotics are more accountable to those whom they harm, administrative agencies and courts may renew an ongoing quality movement within the profession of medicine. They may even spark the professionalization of AI research itself, since professions are institutions of accountability that help assure ongoing self-review and improvement. And if there are concerns about liability over-detering innovation, damages caps may be imposed to calibrate incentives accordingly.

From an individualistic, utilitarian perspective (dominant in mainstream economics), substitutive automation of machines to replace humans in many fields seems to be a foregone conclusion, thanks to a set of interlinked value judgments about the value of cheapening tasks. But within a profession like medicine, matters are more complicated. A renewed political economy of automation demands a role for

⁶³ On the critical distinction between explainable and non-explainable AI in medical automation and robotics, *see* Evans & Pasquale, *supra* note 44, at 26-27. (“To use engineering parlance, the FDA can regulate AI/ML CDS software if it is not intended to function as explainable artificial intelligence. CDS software that makes recommendations falls under the FDA’s regulatory jurisdiction if those recommendations are not intended to be transparent to the health care professionals using the software. On the other hand, if CDS software is transparent enough that a healthcare professional would be able to understand its recommendations and challenge them—that is, when it is not a black box—then Congress excludes it from FDA regulatory oversight.”)

professionals to mediate between patients and complex technologies. Professionals enjoy forms of autonomy, and are burdened by constraints, rare in non-professional fields. Professionals are charged with protecting distinct, non-economic values that society has deemed desirable. Their labor, in turn, reflects, reproduces, and is enriched by those values. Knowledge, skill, and ethics are inextricably intertwined.⁶⁴ In the face of well-hyped automation, professionals ought to reaffirm their own norms. The threat of tort liability for the firms they work for (including AI vendors) gives them some leverage to push back against management demands for premature automation. Indeed, when Marc Law and Sukkoo Kim examined the history of professionalization and occupational licensure, they found patterns of worker self-organization in the United States in the early 20th century that substantially increased consumer protection.⁶⁵ By deterring premature substitutive automation, a liability regime that reduces potential exposure of AI vendors when they complement (rather than substitute for) medical professionals will help ensure a democratization of expertise, including ongoing critical evaluation of medical AI and robotics by physicians and other providers.

Of course, as courts develop such evolving standards of care, they will also face predictable efforts by owners of AI to deflect liability. For example, firms may require their customers or users to sign exculpatory clauses and other contractual limitations on liability by waiving their

⁶⁴ See Frank Paquale, *Synergy and Tradition: The Unity of Research, Service, and Teaching in Legal Education*, 40 J. LEGAL PROF. 25 (2015).

⁶⁵ Marc T. Law & Sukkoo Kim, *Specialization and Regulation: The Rise of Professionals and the Emergence of Occupational Licensing Regulation*, 65 J. ECON. HIST. 723, 725 (2005) (“Thus, professionals may choose to self regulate, or professionals and consumers may seek government regulation to eliminate charlatans, incompetents or frauds and protect the safety and welfare of consumers.”).

right to sue. Asymmetries of power are important here. For example, in medicine, many courts have resisted exculpatory clauses purporting to relieve physicians of responsibility for malpractice, thanks in part to the asymmetrical power of hospitals and their patients.⁶⁶ They should be similarly wary in AI-intensive scenarios, where even greater imbalances of power and knowledge are common.

Policymakers are currently struggling to keep pace with the speed of technological development. Legislators have been hesitant to pass broad statutes, as they are fearful of inhibiting growth and innovation in the space. However, increasingly there is public demand for policy interventions and protections regarding critical technology.⁶⁷ These demands do not necessarily impede economic or technological advancement. Some fields may never get traction if customers cannot be assured that *someone* will be held accountable if an AI fails. Developing appropriate standards of responsibility along the lines prescribed in this article should advance the quality of both artificial intelligence (AI) and intelligence augmentation (IA).

⁶⁶ Nadia N. Sawicki, *Choosing Medical Malpractice*, 93 WASH. L. REV. 891, 893 (2018) (“most courts do ultimately reject defenses based on contract or assumption of risk in medical malpractice cases,” though “they often do so only after carefully examining the characteristics of the patient’s acceptance—an adjudicative approach that is inconsistent with a categorical bar.”).

⁶⁷ Nathalie A. Smuha, *From a “Race to AI” to a “Race to AI Regulation”*: *Regulatory Competition for Artificial Intelligence*, 13 LAW, INNOVATION & TECH. 57, 59, 71 (2021) (“In fact, all over the world, regulators at regional, national, international and supranational level have started assessing the desirability and necessity of new or revised regulatory measures to minimise AI’s adverse impacts, while at the same time maximising its benefits”).

References

- Abbott, Ryan. 2018. The Reasonable Computer: Disrupting the Paradigm of Tort Liability. *George Washington Law Review* 86:1-45.
- Adamson, Adewole S., and Avery Smith. 2018. Machine Learning and Health Care Disparities in Dermatology. *Journal of the American Medical Association Dermatology* 154:1247-1248.
- Ammar, Jamil. 2019. Defective Computer-Aided Design Software Liability in 3D Bioprinted Human Organ Equivalents. *Santa Clara High Technology Law Journal* 35:37-67.
- Aristotle. 2012 (350 B.C.E.). *Politics*, translated by Benjamin Jowett. Los Angeles, CA: Indo-European Publishing.
- Asimov, Isaac. 1950. *I, Robot*. New York, NY: Gnome Press.
- Autor, David. 2014. Polanyi's Paradox and the Shape of Employment Growth. Working Paper No. 20485. National Bureau of Economic Research, Cambridge, MA. Available at <http://www.nber.org/papers/w20485>.
- Barash, Paul G., Bruce F. Cullen, Robert K. Stoelting, Michael K. Cahalan, M. Christine Stock, Rafael Ortega, Sam R. Sharar, and Natalie F. Holt. 2017. *Clinical Anesthesia*. 8th ed. Philadelphia, PA: Wolters Kluwer.
- Bernstein, Anita. 2020. (Almost) No Bad Drugs: Near-Total Products Liability Immunity for Pharmaceuticals Explained. *Washington and Lee Law Review* 77:3-96.
- Blake, Valarie K. 2020. Regulating Care Robots. *Temple Law Review* 92:551-594.

- Braverman, Harry. 1974. *Labor and Monopoly Capital: The Degradation of Work in the Twentieth Century*. New York, NY: Monthly Review Press.
- Carr, Nicholas. 2015. *The Glass Cage: How Our Computers Are Changing Us*. New York, NY: W. W. Norton & Company.
- Chin, Andrew. 2017. Surgically Precise but Kinematically Abstract Patents. *Houston Law Review* 55:267-319.
- Citron, Danielle Keats. 2007. Reservoirs of Danger: The Evolution of Public and Private Law at the Dawn of the Information Age. *Southern California Law Review* 80:241-297.
- Elish, Madeleine, and Tim Hwang. 2015. Praise the Machine! Punish the Human! The Contradictory History of Accountability in Automated Aviation. Working Paper No. 1. Data & Society Research Institute, New York, NY.
- Evans, Barbara J., and Frank Pasquale. 2022. Product Liability Suits for FDA-Regulated AI/ML Software. Pp. 22-35 in *The Future of Medical Device Regulation: Innovation and Protection*, edited by I. Glenn Cohen, Timo Minssen, W. Nicholson Price, II, Christopher Robertson and Carmel Shachar. New York, NY: Cambridge University Press.
- Goldacre, Ben. 2013. *Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients*. London: Fourth Estate.
- Goldberg, Margo. 2012. The Robotic Arm Went Crazy! The Problem of Establishing Liability in A Monopolized Field. *Rutgers Computer & Technology Law Journal* 38:225-253.
- Goldin, Claudia, and Lawrence F. Katz. 2008. *The Race Between Education and Technology*. Cambridge, MA: Harvard University Press.

- Goudra, Basavana G., and Preet M. Singh. 2014. SEDASYS, Sedation, and the Unknown. *Journal of Clinical Anesthesia* 26:334-336.
- Hamilton-Piercy, Meghan. 2007. Cybersurgery: Why the United States Should Embrace This Emerging Technology. *Journal of High Technology Law* 7:203-226.
- Hoffman, Sharona, and Andy Podgurski. 2008. Finding a Cure: The Case for Regulation and Oversight of Electronic Health Record Systems. *Harvard Journal of Law & Technology* 22:103-165.
- Keating, Gregory. 2001. The Theory of Enterprise Liability and Common Law Strict Liability. *Vanderbilt Law Review* 54:1285-1335.
- Kesselheim, Aaron S. 2010. Permitting Product Liability Litigation for FDA-Approved Drugs and Devices Promotes Patient Safety. *Clinical Pharmacology and Therapeutics* 87:645-647.
- Latour, Bruno. 2005. *Reassembling the Social: An Introduction to Actor-Network-Theory*. Oxford: Oxford University Press.
- Law, Marc T., and Sukko Kim. 2005. Specialization and Regulation: The Rise of Professionals and the Emergence of Occupational Licensing Regulation. *Journal of Economy History* 65:723-756.
- Lawrence, Matthew J.B. 2009. In Search of an Enforceable Medical Malpractice Exculpatory Agreement: Introducing Confidential Contracts as a Solution to the Doctor-Patient Relationship Problem. *New York University Law Review* 84:850-879.
- Lenzer, Jeanne. 2017. *The Danger Within Us: America's Untested, Unregulated Medical Device Industry and One Man's Battle to Survive It*. New York, NY: Little, Brown and Company.
- Levy, Karen E.C. 2016. The Contexts of Control: Information, Power, and Truck-Driving Work. *The Information Society* 31:160-174.

- Lindenfeld, Eric. 2016. 3D Printing of Medical Devices: CAD Designers as the Most Realistic Target for Strict, Product Liability Lawsuits. *University of Missouri-Kansas City Law Review* 85:79-103.
- McCluskey, Martha T., Frank Pasquale, and Jennifer Taub. 2016. Law and Economics: Contemporary Approaches. *Yale Law and Policy Review* 35:297-308.
- Novara, Giacomo, Vincenzo Ficarra, Raymond C. Rosen, Walter Artibani, Anthony Costello, James A. Eastham, Markus Graefen, Giorgio Guazzoni, Shahrokh F. Shariat, Jens-Uwe Stolzenburg, Hendrik Van Poppel, Filiberto Zattoni, Francesco Montorsi, Alexandre Mottrie, and Timothy G. Wilson. 2012. Systematic Review and Meta-analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Prostatectomy. *European Urology* 62:431-452.
- Parasidis, Efthimios. 2018. Clinical Decision Support: Elements of a Sensible Legal Framework. *Journal of Health Care Law and Policy* 20:183-228.
- Pasquale, Frank. 2010. Access to Medicine in an Era of Fractal Inequality. *Annals of Health Law* 19:269-310.
- . 2010. Ending the Specialty Hospital Wars: A Plea for Pilot Programs as Information-Forcing Regulatory Design. Pp. 235-278 in *The Fragmentation of U.S. Health Care: Causes and Solutions*, edited by Einer Elhauge. Oxford: Oxford University Press.
- . 2013. Grand Bargains for Big Data: The Emerging Law of Health Information. *Maryland Law Review* 72:682-772.
- . 2015. Synergy and Tradition: The Unity of Research, Service, and Teaching in Legal Education. *Journal of the Legal Profession* 40:25-49.

- . 2019. Six Horsemen of Irresponsibility. *Maryland Law Review* 79:105-113.
- . 2020. *New Laws of Robotics: Defending Human Expertise in the Age of AI*. Cambridge, MA: Belknap Press.
- Perez, Caroline Criado. 2019. *Invisible Women: Data Bias in a World Designed for Men*. New York, NY: Abrams Press.
- Pinkney, Kevin R. 2002. Putting Blame Where Blame Is Due: Software Manufacturer and Customer Liability for Security-Related Software Failure. *Albany Law Journal of Science and Technology* 13:43-82.
- Popejoy, Alice B., Deborah I. Ritter, Kristy Crooks, Erin Currey, Stephanie M. Fullerton, Lucia A. Hindorff, Barbara Koenig, Erin M. Ramos, Elena P. Sorokin, Hannah Wand, Mathew W. Wright, James Zou, Christopher R. Gignoux, Vence L. Bonham, Sharon E. Plon, Carlos D. Bustamante, and Clinical Genome Resource (ClinGen), Ancestry and Diversity Working Group (ADWG). 2018. The Clinical Imperative for Inclusivity: Race, Ethnicity, and Ancestry (REA) in Genomics. *Human Mutation* 39:1713-1720.
- Price, W. Nicholson, II, Sara Gerke, and I. Glenn Cohen. 2019. Potential Liability for Physicians Using Artificial Intelligence. *The Journal of the American Medical Association* 322:1765-1766.
- Radin, Margaret Jane. 2012. *Boilerplate: The Fine Print, Vanishing Rights, and the Rule of Law*. Princeton, NJ: Princeton University Press.
- Reutiman, Joseph L. 2012. Defective Information: Should Information Be a “Product” Subject to Products Liability Claims?. *Cornell Journal of Law and Public Policy* 22:181-203.
- Saeidi, Hamed, Justin D. Opfermann, Michael Kam, Shuwen Wei, Simon Leonard, Michael H. Hsieh, Jin U. Kang, and Axel Krieger.

2022. Autonomous Robotic Laparoscopic Surgery for Intestinal Anastomosis. *Science Robotics* 7:eabj2908.
- Sawicki, Nadia N. 2018. Choosing Medical Malpractice. *Washington Law Review* 93:891-966.
- Scott, Michael D. 2008. Tort Liability for Vendors of Insecure Software: Has the Time Finally Come?. *Maryland Law Review* 67:425-484.
- Shademan, Azad, Ryan S. Decker, Justin D. Opfermann, Simon Leonard, Axel Krieger, and Peter C. W. Kim. 2016. Supervised Autonomous Robotic Soft Tissue Surgery. *Science Translational Medicine* 8:337ra64.
- Simshaw, Drew, Nicolas Terry, Kris Hauser, and M.L. Cummings. 2016. Regulating Healthcare Robots: Maximizing Opportunities While Minimizing Risks. *Richmond Journal of Law & Technology* 22:1-38.
- Smuha, Nathalie A. 2021. From a “Race to AI” to a “Race to AI Regulation”: Regulatory Competition for Artificial Intelligence. *Law, Innovation and Technology* 13:57-84.
- Turner, Jacob. 2019. *Robot Rules*. London: Palgrave Macmillan.
- Valverde, Mariana. 2007. Reassembling the Social: An Introduction to Actor-Network Theory. By Bruno Latour (book review). *Law and Society Review* 41:744-746.
- Wachter, Robert. 2015. *The Digital Doctor: Hope, Hype, and Harm at the Dawn of Medicine’s Computer Age*. New York, NY: McGraw-Hill.
- Zollers, Frances E., Andrew McMullin, Sandra N. Hurd, and Peter Shears. 2005. No More Soft Landings for Software: Liability for Defects in an Industry That Has Come of Age. *Santa Clara Computer and High Technology Law Journal* 21:745-782.

自主權的代價

—— 輔助性與替代性醫療機器人和人工智慧技術的 侵權責任標準

*Frank Pasquale**

摘要

在醫療領域，當人工智慧或機器人技術僅為專業人士提供工具性協助時，「有效的人為介入原則」傾向於將侵權責任從設備製造供應商轉移到操作設備之專業人員身上。然而，專業人員在此種情況下不應承擔所有責任。工具可能帶有瑕疵，而販售有瑕疵的輔助性人工智慧及機器人技術的製造供應商則應對其過失負責。此時原告則仍應舉證，證明專業醫事人員及提供工具的製造商，應對本可防免的負面結果負有賠償責任。

相對地，當人工智慧和機器人技術取代、而非只輔助醫事專業人員時，此類計算系統的供應商，則須對失誤和事故擔負更多責任。醫療領域對專業人士監督先進技術運用有既存標準。一旦醫療自動化完全替代真人操作，避開專業人員的人為監督，從而危及患者時，即對患者構成有瑕疵且不合理的危險。不過在損害賠償之訴中，替代性人工智慧技術的製造供應商，應得以人工智慧之表現，相對於現有人為或人機的照護標準，來解釋應如何減輕其賠償金額。此種解釋責任將能發揮重要的資訊強制作用，因為這個領域的公眾理解，常受限於營業秘密。

* 康乃爾大學法學院教授。

正如法律和政治經濟學方法所表明的，法律對於新技術市場不可能保持中立。法律構建了新技術市場，促使某些未來發展更易成真，或使另一些發展不易實現。區分一項技術，究竟係替代、或輔助人類專業知識或者輔助專業人士，不僅對勞工政策、對自動化的政治經濟學、也對侵權法，均至關重要。

關鍵詞：人工智慧（AI）、機器人技術、責任、自動化、自動化決策、醫療事故、企業責任、專業人員、政治經濟學、臨床決策支援軟體。